S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ENTX · Entera Bio Ltd. Ordinary Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$3.02
+0.02
(+0.67%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.02
$2.96
$3.10
52-WEEK RANGE
$3.02
$0.91
$4.20
What's happening
- ENTX is up 0.67% today, trading at $3.02. — Live quote
- Volume today (33,158) is well below its 3-month average of 2,024,460. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.14 actual vs. $-0.08 estimated (-71.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ENTX
+55.67%
vs S&P 500
+42.89%
1-YEAR RETURN
ENTX
+22.27%
vs S&P 500
+7.71%
6-MONTH RETURN
ENTX
+151.67%
3-MONTH RETURN
ENTX
+54.08%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.14
Est. $-0.08
MISS -71.6%
2026-04-26 (Q1 2026)
$-0.07
Est. $-0.15
BEAT +54.2%
2026-01-26 (Q4 2025)
$-0.07
Est. $-0.09
BEAT +23.7%
2025-10-26 (Q3 2025)
$-0.07
Est. $-0.09
BEAT +23.7%
Valuation Measures & Ratios
Enterprise Value4$520.9M
Forward P/E5—
PEG Ratio6-0.23
Price / Sales (TTM1)2386.56
Price / Book712.01
EV4 / Revenue2335.85
EV4 / EBITDA—
Profit Margin-4525.11%
Operating Margin-4522.87%
Return on Equity (ROE8)-147.19%
Return on Assets (ROA9)-103.22%
Avg Volume (3M)2,024,460
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,403,597
Change from Prior Settlement+87.51%
% of Float—
Days to Cover (Short Ratio)5.18
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +22.3%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -35.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -4525.1%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ENTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $42.0K | $42.0K | $57.0K | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $9.0K | — |
| Operating income | -$4.6M | -$3.5M | -$3.3M | -$2.7M | -$2.6M | -$3.0M | -$2.2M | -$2.1M |
| Net income | -$7.3M | -$3.5M | -$3.2M | -$2.7M | -$2.6M | -$3.0M | -$2.1M | -$2.0M |
| EPS (diluted) | $0.14 | $0.07 | $0.07 | $0.06 | $0.06 | $0.08 | $0.06 | $0.05 |
| EPS (basic) | $0.14 | $0.07 | $0.07 | $0.06 | $0.06 | $0.08 | $0.06 | $0.05 |
| Operating margin | — | — | — | — | -$6.1K | -$7.2K | -$3.8K | — |
| Net margin | — | — | — | — | -$6.1K | -$7.2K | -$3.8K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $19.5M | $13.1M | $16.0M | $17.4M | $19.7M | $21.6M | $9.4M | $7.7M |
| Total liabilities | $12.2M | $2.4M | $2.9M | $2.2M | $2.4M | $2.2M | $1.3M | $1.3M |
| Stockholders' equity | $7.3M | $10.7M | $13.1M | $15.2M | $17.3M | $19.4M | $8.1M | $6.5M |
| Total current assets | $18.9M | $12.5M | $15.3M | $17.0M | $19.3M | $21.2M | $9.0M | $7.3M |
| Total current liabilities | $2.1M | $1.6M | $2.2M | $1.6M | $1.8M | $1.6M | $1.2M | $1.1M |
| Cash & equivalents | $11.3M | $4.1M | $7.1M | $8.6M | $10.9M | $12.6M | $8.7M | $6.9M |
| Accounts receivable | — | — | $0 | $0 | $0 | $126.0K | $126.0K | $42.0K |
| Other current assets | $144.0K | $256.0K | $107.0K | $262.0K | $192.0K | $165.0K | $186.0K | $89.0K |
| Property, plant & equipment | $121.0K | $127.0K | $134.0K | $114.0K | $79.0K | $57.0K | $57.0K | $65.0K |
| Accounts payable | $575.0K | $274.0K | $448.0K | $216.0K | $383.0K | $134.0K | $132.0K | $184.0K |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | $393.0K | — | — | — | $0 | — |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained earnings | -$136.2M | -$128.9M | -$125.4M | -$122.3M | -$119.2M | -$116.5M | -$113.9M | -$111.6M |
| Accumulated other comprehensive income (loss) | $41.0K | $41.0K | $41.0K | $41.0K | $41.0K | $41.0K | $41.0K | $41.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.5M | -$3.1M | -$1.8M | -$2.5M | -$1.6M | -$1.4M | -$1.5M | -$2.2M |
| Investing cash flow | -$3.0K | $0 | -$27.0K | -$43.0K | -$29.0K | -$8.0K | -$3.0K | $0 |
| Financing cash flow | $10.0M | $130.0K | $174.0K | $250.0K | -$51.0K | $13.3M | $3.2M | $13.0K |
| Free cash flow | -$3.5M | -$3.1M | -$1.9M | -$2.5M | -$1.7M | -$1.4M | -$1.5M | -$2.2M |
| Capital expenditures | $3.0K | $0 | $27.0K | $43.0K | $29.0K | $8.0K | $3.0K | $0 |
| Share-based compensation | $624.0K | $672.0K | $710.0K | $927.0K | $509.0K | $604.0K | $566.0K | $928.0K |
| Deferred income taxes | — | — | $0 | — | — | — | $14.0K | $0 |
| Change in accounts receivable | $0 | — | $0 | $0 | -$126.0K | — | -$7.0K | $76.0K |
| Change in accounts payable | $301.0K | -$174.0K | $232.0K | -$167.0K | $249.0K | $2.0K | -$52.0K | $115.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $42.0K | $181.0K | $0 | $134.0K | $571.0K |
| Gross profit | $0 | $9.0K | $0 | $33.0K | $198.0K |
| Operating income | -$11.5M | -$9.6M | -$8.9M | -$13.0M | -$12.2M |
| Net income | -$11.4M | -$9.5M | -$8.9M | -$13.1M | -$12.2M |
| EPS (diluted) | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 |
| EPS (basic) | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 |
| Operating margin | -$27.4K | -$5.3K | — | -$9.7K | -$2.1K |
| Net margin | -$27.2K | -$5.3K | — | -$9.8K | -$2.1K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $16.0M | $9.4M | $11.8M | $13.1M | $26.0M |
| Total liabilities | $2.9M | $1.3M | $1.4M | $1.4M | $3.4M |
| Stockholders' equity | $13.1M | $8.1M | $10.4M | $11.8M | $22.6M |
| Total current assets | $15.3M | $9.0M | $11.3M | $12.8M | $25.3M |
| Total current liabilities | $2.2M | $1.2M | $1.1M | $1.3M | $3.2M |
| Cash & equivalents | $7.1M | $8.7M | $11.0M | $12.3M | $24.9M |
| Accounts receivable | $0 | $126.0K | $0 | $246.0K | $183.0K |
| Other current assets | $415.0K | $186.0K | $238.0K | $294.0K | $254.0K |
| Property, plant & equipment | $134.0K | $57.0K | $100.0K | $139.0K | $156.0K |
| Accounts payable | $448.0K | $132.0K | $83.0K | $17.0K | $166.0K |
| Deferred revenue (current) | — | — | — | $0 | $15.0K |
| Other non-current liabilities | $393.0K | $0 | — | — | — |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | — | — |
| Retained earnings | -$125.4M | -$113.9M | -$104.4M | -$95.5M | -$82.4M |
| Accumulated other comprehensive income (loss) | $41.0K | $41.0K | $41.0K | $41.0K | $41.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.4M | -$6.8M | -$7.3M | -$12.5M | -$9.1M |
| Investing cash flow | -$107.0K | -$3.0K | -$17.0K | -$102.0K | -$17.0K |
| Financing cash flow | $13.7M | $4.5M | $6.0M | $13.0K | $25.4M |
| Free cash flow | -$7.5M | -$6.8M | -$7.3M | -$12.5M | -$9.1M |
| Capital expenditures | $107.0K | $3.0K | $17.0K | $47.0K | $17.0K |
| Share-based compensation | $2.8M | $2.6M | $1.7M | $2.2M | $1.9M |
| Deferred income taxes | $0 | $14.0K | $29.0K | $174.0K | -$217.0K |
| Change in accounts receivable | -$126.0K | $126.0K | -$246.0K | $63.0K | -$72.0K |
| Change in accounts payable | $316.0K | $49.0K | $66.0K | -$149.0K | $2.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ENTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
No 13F institutional ownership reported for this symbol.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-01 to 2026-08-07
Recent transactions
- Most recent: Rubin Steven D (Director) — Grant / award of 19,117 shares on 2026-08-07.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Rubin Steven D | Director | Grant / award | 2026-08-07 | 19,117 |
| Malca Yonatan | Director | Grant / award | 2026-08-07 | 22,815 |
| Taitel Haya | Director | Grant / award | 2026-08-07 | 20,790 |
| Ellis Sean | Director | Grant / award | 2026-08-07 | 20,034 |
| Germano Geno J | Director | Grant / award | 2026-08-07 | 25,014 |
| Toledano Miranda Jayne | Chief Executive Officer | Grant / award | 2026-07-14 | 347,567 |
| Galitzer Hillel | Chief Operating Officer | Grant / award | 2026-05-07 | 72,993 |
| Yaacov-Garbeli Dana | Chief Financial Officer | Grant / award | 2026-05-07 | 58,394 |
| Burshtein Gregory | Chief of R&D | Grant / award | 2026-05-07 | 87,591 |
| OSTROV GERALD M | Director | Grant / award | 2026-01-01 | 28,721 |
| LIEBERMAN GERALD M | Director | Grant / award | 2026-01-01 | 38,294 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-07 | Rubin Steven D | Director | Grant / award | 19,117 | $0.00 |
| 2026-08-07 | Malca Yonatan | Director | Grant / award | 22,815 | $0.00 |
| 2026-08-07 | Taitel Haya | Director | Grant / award | 20,790 | $0.00 |
| 2026-08-07 | Ellis Sean | Director | Grant / award | 20,034 | $0.00 |
| 2026-08-07 | Germano Geno J | Director | Grant / award | 25,014 | $0.00 |
| 2026-07-14 | Toledano Miranda Jayne | Chief Executive Officer | Grant / award | 347,567 | $0.00 |
| 2026-07-14 | Toledano Miranda Jayne | Chief Executive Officer | Grant / award | 72,993 | $0.00 |
| 2026-05-07 | Galitzer Hillel | Chief Operating Officer | Grant / award | 72,993 | $0.00 |
| 2026-05-07 | Yaacov-Garbeli Dana | Chief Financial Officer | Grant / award | 58,394 | $0.00 |
| 2026-05-07 | Burshtein Gregory | Chief of R&D | Grant / award | 87,591 | $0.00 |
| 2026-03-09 | Germano Geno J | Director | Open market purchase | 20,000 | $1.30 |
| 2026-03-05 | Ellis Sean | Director | Open market purchase | 10,000 | $1.23 |
| 2026-02-12 | Rubin Steven D | Director | Open market purchase | 5,000 | $1.49 |
| 2026-02-10 | Taitel Haya | Director | Open market purchase | 7,500 | $1.48 |
| 2026-02-10 | Germano Geno J | Director | Open market purchase | 20,000 | $1.49 |
| 2026-02-09 | Rubin Steven D | Director | Open market purchase | 10,000 | $1.20 |
| 2026-02-09 | Ellis Sean | Director | Open market purchase | 18,000 | $1.24 |
| 2026-01-01 | OSTROV GERALD M | Director | Grant / award | 28,721 | $0.00 |
| 2026-01-01 | Ellis Sean | Director | Grant / award | 25,371 | $0.00 |
| 2026-01-01 | Malca Yonatan | Director | Grant / award | 30,157 | $0.00 |
| 2026-01-01 | LIEBERMAN GERALD M | Director | Grant / award | 38,294 | $0.00 |
| 2026-01-01 | Taitel Haya | Director | Grant / award | 26,329 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:17 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 8-K | 2026-10-06 | View on SEC.gov → |
| 2026-08-18 | 8-K | 2026-08-18 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about ENTX (Entera Bio Ltd. Ordinary Shares). Links open the publisher — we don’t host full articles.
-
CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,SRBK,LUCK,PCF,GAIA,CFBK,MDRR,SPMC,GEF-B,FRD,MDBH,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
CABA,PFX,ELUT,ZBIO,HYPD,SELF,ENTX,SRBK,MAIA,LUCK,PCF,MDRR,GAIA,SPMC,GEF-B,MDBH,IRIX,RAL,BOTJ,RNXT,AIRJ,SCKT | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-21 -
CABA,PFX,ELUT,ZBIO,HYPD,ALT,SELF,ENTX,SRBK,PCF,LUCK,GAIA,CFBK,MDRR,SPMC,GEF-B,FRD,MDBH,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
CABA,PFX,ELUT,ZBIO,HYPD,ALT,SELF,ENTX,SRBK,LUCK,PCF,CFBK,MDRR,GAIA,GEF-B,SPMC,MDBH,FRD,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
Entera Bio Ltd. (ENTX) Ticks Higher to $3.02 as Buyers Defend Key Support - Dividend Growth Stocks
https://www.dars.gov.et/ · 2026-10-21 -
CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,BLIN,LUCK,PCF,CFBK,MDRR,GAIA,VSTS,GEF-B,SPMC,MDBH,FRD,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
Entera Bio Ltd. (ENTX) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,BLIN,PCF,LUCK,CFBK,MDRR,GAIA,VSTS,SPMC,GEF-B,FRD,MDBH,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-20
No headlines in this category right now — try “All”.